Clinical trials
Nontuberculous Mycobacterial Pulmonary Disease clinical trials
Below are recruiting nontuberculous mycobacterial pulmonary disease clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06838442Recruiting
Exercise and airway clearance education for NTM lung disease
This trial studies whether a program of exercise and airway clearance education helps people with nontuberculous mycobacterial (NTM) lung disease. It aims to improve breathing and quality of life.
Seongnam-si, Gyeonggi-doAges 20 years+ - NCT04078412Enrolling by invitation
Registry for adults with nontuberculous lung infection
This is a research registry that collects information from adults diagnosed with nontuberculous mycobacterial (NTM) lung disease. It may help doctors better understand the disease and improve care over time.
SeoulAges 20 years+ - NCT05678166Recruiting
Testing a blood marker to predict worsening lung mycobacterial disease
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
TaipeiAges 20 years+ - NCT04921943RecruitingPhase 4
Hypertonic saline to treat MAC lung infection
This trial tests whether inhaled hypertonic saline can improve symptoms and lung health in people with a specific lung infection called MAC. It targets adults with confirmed MAC infection and bronchiectasis who are not already on certain MAC medications.
New York, New YorkAges 18 years+ - NCT05192057RecruitingPhase 4
Inhaling salty steam for lung MAC infection
This trial studies whether inhaling hypertonic (very salty) saline helps treat nodular-bronchiectatic lung disease caused by Mycobacterium avium complex (MAC). It may help reduce ongoing infection and symptoms if you have the right type of MAC lung pattern and have not recently started the usual MAC treatments.
NijmegenAges 18 years+ - NCT06488495Recruiting
Exercise program for nontuberculous mycobacterium lung disease
This trial tests whether a structured exercise program can improve symptoms and quality of life in people with nontuberculous mycobacterial (NTM) lung disease. If you have a confirmed NTM lung infection and are having respiratory symptoms, this study may help you build strength and better manage your condition.
SeoulAges 40–80 - NCT06262282Enrolling by invitation
Phage therapy for stubborn NTM infection in cystic fibrosis
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
Birmingham, AlabamaAges 6 years+ - NCT07174076RecruitingPhase 4
Cordyceps sinensis to prevent MAC lung disease from coming back
This study looks at whether cordyceps sinensis, a natural fungus, can help prevent a lung infection caused by MAC bacteria from returning. If you have finished treatment for MAC lung disease and your sputum tests are negative, you may be able to join.
Hefei, AnhuiAges 18–75 - NCT07213765RecruitingPhase 4
Short-term antibiotics for MAC lung disease
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
Hefei, AnhuiAges 18–75 - NCT07292714RecruitingPhase 2
Testing 9MW1911 for people with moderate to severe COPD
This trial tests a new medication called 9MW1911 to see if it can help people with moderate to severe COPD who have had recent flare-ups. It is for current or former smokers ages 40 to 75 who are already on standard COPD treatments.
Chizhou, AnhuiAges 40–75 - NCT07084402RecruitingPhase 4
Effect of Contezolid on MAC lung disease
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
Beijing, Beijing MunicipalityAges 18–75 - NCT06585020RecruitingPhase 2
Inhaled antibiotic for Mycobacterium xenopi lung infection
This trial tests an inhaled antibiotic (amikacin liposome) for people with a lung infection caused by a germ called Mycobacterium xenopi. The goal is to see if this treatment can help fight the infection with fewer side effects.
AmiensAges 18 years+
Hear when a new Nontuberculous Mycobacterial Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nontuberculous mycobacterial pulmonary disease?
- Yes. Clin2 currently lists 12 recruiting nontuberculous mycobacterial pulmonary disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nontuberculous mycobacterial pulmonary disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nontuberculous mycobacterial pulmonary disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.